These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 11712769)

  • 21. A rationale for treatment of endothelial dysfunction in hypertension.
    Ruschitzka F; Corti R; Noll G; Lüscher TF
    J Hypertens Suppl; 1999 Feb; 17(1):S25-35. PubMed ID: 10340841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelial factors and microvascular hypertensive disease.
    Rizzoni D; Agabiti-Rosei E
    J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S15-8. PubMed ID: 11811369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of calcium channel and renin-angiotensin system blockade on intravascular and neurohormonal mechanisms of hypertensive vascular disease.
    Mizuno Y; Jacob RF; Mason RP
    Am J Hypertens; 2008 Oct; 21(10):1076-85. PubMed ID: 18756260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems.
    Dielis AW; Smid M; Spronk HM; Hamulyak K; Kroon AA; ten Cate H; de Leeuw PW
    Hypertension; 2005 Dec; 46(6):1236-42. PubMed ID: 16286563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.
    Iimura O; Shimamoto K
    Adv Exp Med Biol; 1989; 247A():39-48. PubMed ID: 2532450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia.
    Pitt B
    Am J Cardiol; 1997 Mar; 79(5A):24-8. PubMed ID: 9127618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelial function and bradykinin in humans.
    Hornig B; Drexler H
    Drugs; 1997; 54 Suppl 5():42-7. PubMed ID: 9429844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hypertension and arteriosclerosis].
    Sasamura H; Itoh H
    Nihon Rinsho; 2011 Jan; 69(1):125-30. PubMed ID: 21226272
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary kallikrein excretion and blood pressure response to angiotensin converting enzyme inhibitors and calcium antagonists in hypertensive patients.
    Dessì-Fulgheri P; Espinosa E; Zingaretti O; Guazzarotti F; Sarzani R; Pupita G; Sturbini S; Catalini R; Rappelli A
    J Hypertens; 1993 Jul; 11(7):725-30. PubMed ID: 8228191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium antagonists and ACE inhibitors. Effect on endothelium and vascular smooth muscle.
    Lüscher TF; Yang Z
    Drugs; 1993; 46 Suppl 2():121-32. PubMed ID: 7512465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study.
    Higashi Y; Sasaki S; Nakagawa K; Ueda T; Yoshimizu A; Kurisu S; Matsuura H; Kajiyama G; Oshima T
    J Am Coll Cardiol; 2000 Feb; 35(2):284-91. PubMed ID: 10676671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
    Schalekamp MA; Derkx FH; van den Meiracker AH
    J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcium channel blockers, endothelial dysfunction, and combination therapy.
    Schulman IH; Zachariah M; Raij L
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):40-5. PubMed ID: 16640172
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial.
    Pepine CJ; Handberg EM; Cooper-DeHoff RM; Marks RG; Kowey P; Messerli FH; Mancia G; Cangiano JL; Garcia-Barreto D; Keltai M; Erdine S; Bristol HA; Kolb HR; Bakris GL; Cohen JD; Parmley WW;
    JAMA; 2003 Dec; 290(21):2805-16. PubMed ID: 14657064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Endothelium and endogenous fibrinolysis].
    Nordt TK; Bode C
    Z Kardiol; 2000 Mar; 89(3):219-26. PubMed ID: 10798278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pathophysiology of mild hypertension: role of endothelial function].
    Matsuoka H; Imaizumi T
    Nihon Rinsho; 2008 Aug; 66(8):1517-24. PubMed ID: 18700551
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pharmacotherapy of arteriosclerosis and its complications. Effect of ACE inhibitors and HMG-CoA-reductase inhibitors].
    Tschudi MR; Noll G; Lüscher TP
    Schweiz Med Wochenschr; 1997 Apr; 127(15):636-49. PubMed ID: 9198890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.